EU and US rush to nail down final details and lock in trade deal
The euro dropped the most in over two months against the US dollar on Monday (Jul 28), plunging more than 1 per cent. That's after the common currency had surged to a near three-year high last week on the prospect of an agreement with the US.
The EU over the weekend agreed to accept a 15 per cent tariff on most of its exports, while the bloc's average tariff rate on American goods should drop below 1 per cent once the deal goes into effect. Brussels also said that it would purchase US$750 billion in American energy products and invest US$600 billion more in the US.
'The free trade principles that have underpinned transatlantic prosperity since the end of World War II are being systematically dismantled,' Karin Karlsbro, a Swedish member of the European Parliament's trade committee, said. 'The risk of European economic and political marginalisation grows with each concession made.'
German Chancellor Friedrich Merz, who initially cheered the deal as having 'succeeded' in avoiding a trade conflict and enabling the EU to safeguard its interests, seemed to sour on the accord.
'The German economy will suffer significant damage from these tariffs,' he told reporters on Monday. 'I'm pretty sure this won't be limited to Germany and Europe. We will also see the consequences of this trade policy in America.'
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Sign Up
Sign Up
French Prime Minister Francois Bayrou was also critical, saying on social media: 'It's a dark day when an alliance of free peoples, united to affirm their values and defend their interests, opts for submission.'
The EU and US will seek to clinch a non-legally binding joint statement by Aug 1 that will expand on some of the elements negotiated over the weekend, according to a senior EU official. Once the statement is finalised, the US will begin lowering its tariffs on specific sectors, in particular for cars and car parts, which currently face a 27.5 per cent levy.
The two sides will then start work on a legally binding text, said the official, who spoke on the condition of anonymity. The content and legal form of this document aren't clear, but it would require the support of at least a qualified majority of EU countries and possibly the European Parliament.
The EU official said that reaching a consensus on the legal text could take a long time; many trade accords require years of negotiations. The EU will not start implementing the terms it agreed to, such as lowering tariffs on US products, until after this legal text is approved, according to the official.
'The agreement removes some tail downside risks but is short on details, which will need to be thrashed out over the coming weeks, risking new volatility,' Oliver Rakau, chief Germany economist at Oxford Economics, said. 'Uncertainty is likely to remain elevated.'
European Commission President Ursula von der Leyen said that the US agreed to bilaterally lower tariffs to zero on certain strategic products, including aircraft and component parts, certain generics, semiconductor equipment and certain agricultural products.
One potential sticking point in negotiations will be EU metal exports, which currently have a 50 per cent tariff rate. The EU is pushing for a quota on metals that would lower the levies on a certain volume of goods, while anything above that would pay the 50 per cent rate, according to the EU official.
'Uncertainty remains regarding all the details concerning the European steel industry,' said Axel Eggert, director-general of the European Steel Association.
Discussions are ongoing on whether some goods, such as wine and spirits, would be exempt from the 15 per cent tariff rate, the EU official said.
Another possible issue is the EU's promise to purchase US$750 billion of American energy imports over three years, an integral part to securing the deal. Yet it's hard to see how the EU attains such ambitious flows over such a short time frame.
Total energy imports from the US accounted for less than US$80 billion last year, far short of the promise made by von der Leyen to Trump. Total US energy exports were just over US$330 billion in 2024.
The EU's pledge to invest an additional US$600 billion in the US is just as problematic. The investment is just an aggregate of pledges by companies and not a binding target, as the European Commission cannot commit to such a goal, said the EU official.
The uncertainty from the trade war has weighed on EU economic forecasts, with the commission in May cutting its GDP growth expectations for the year to 1.1 per cent. It projected a 1.5 per cent rate in November.
Despite the critics, the commission, which handles trade matters for the EU, insists this was the only course of action.
'This is clearly the best deal we could get under very difficult circumstances,' Maros Sefcovic, the EU's trade chief, told reporters on Monday. BLOOMBERG
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


International Business Times
an hour ago
- International Business Times
Trump Demands Drug Price Cuts in Letters to 17 Pharma Giants Summary
US President Donald Trump has sent letters to 17 major pharmaceutical companies demanding they cut prescription drug prices in the United States. The letters, released Thursday by the White House, outline his plan to match U.S. prices with those in other developed countries. President Donald Trump addessses the nation after U.S. bombed Iran's nuclear facilities X Trump recently signed an executive order requiring drugmakers to offer "most-favored-nation" pricing. This means companies must sell medications to U.S. patients at the lowest price they offer elsewhere. If drug companies do not comply, Trump warned the government could import cheaper alternatives or take other steps. Companies that received the letters include Pfizer, Eli Lilly, Johnson & Johnson, Merck, Sanofi, and AstraZeneca. Trump had previously criticized earlier proposals from the industry, saying they prioritized profits over patient care. He also demanded that drugmakers return any excess profits made by raising prices overseas to compensate American taxpayers. Shares of major pharmaceutical firms fell after the announcement. Pfizer, Eli Lilly, and Gilead each dropped by around 2%, while a broader index of drug stocks declined 3%. Trump also suggested a system where companies can sell drugs directly to patients, bypassing middlemen, but only if they agree to international pricing rules. The president gave drugmakers a deadline of September 29 to respond with binding commitments. Health experts are skeptical that companies will meet Trump's demands. Some analysts believe the proposals are unlikely to result in immediate price changes, describing them as more political pressure than enforceable policy. Still, several companies, including Pfizer and Novartis, said they are open to working with the administration. Pfizer confirmed its ongoing talks with Trump officials to improve access and affordability for U.S. patients. U.S. drug prices remain among the highest in the world, with patients often paying nearly three times more than those in other developed countries. Drugmakers argue that sharp price cuts could harm innovation, but Trump insists bold action is needed to protect Americans from high costs.

Straits Times
2 hours ago
- Straits Times
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Sign up now: Get ST's newsletters delivered to your inbox Moderna has accused Pfizer and BioNTech of violating its intellectual property rights with regard to mRNA technology. LONDON - US pharmaceutical giant Pfizer and German firm BioNTech lost on Aug 1 a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. 'The judge made no error of law or principle' in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal the Aug 1 ruling to Britain's Supreme Court. 'Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid,' Pfizer said in a statement. 'This decision has no immediate impact on Pfizer and BioNTech.' Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. The Aug 1 decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with the Aug 1 ruling and would 'continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology'. A UK court was told in 2024 the firms had spent £19 million (S$32 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid-19 pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide 'appropriate compensation'. AFP


CNA
2 hours ago
- CNA
Exclusive-Prosus set to win EU nod for $4.74 billion Just Eat deal, sources say
BRUSSELS :Dutch technology investor Prosus is set to win EU antitrust approval for its 4.1 billion euro ($4.7 billion) bid for Just Eat Takeaway, after agreeing to sell down its stake in Delivery Hero, people with direct knowledge of the matter said. Amsterdam-headquartered Prosus, which is majority owned by South Africa's Naspers, announced the deal in February, banking on its artificial intelligence capability to boost Just Eat Takeaway, Europe's biggest meal delivery company. Prosus last month offered to incrementally sell down its 27.4 per cent stake in Delivery Hero and to give up its board seat to address EU competition concerns, other people familiar with the matter had told Reuters. Delivery Hero and Just Eat Takeaway compete with each other in Austria, Bulgaria, Italy, Poland and Spain. The European Commission, which is now seeking market feedback to Prosus' offer and will decide on the deal by August 11, declined to comment. Prosus also declined to comment. The deal would make Prosus the world's fourth-largest food delivery company after Meituan, DoorDash and Uber, according to ING analysts. Delivery Hero and its Spanish unit Glovo were fined 329 million euros by the EU antitrust watchdog in June for taking part in a cartel which included an agreement to divide up markets among themselves and not to poach each other's employees. ($1 = 0.8658 euros)